Of the over 1,900 errors already reported in the gene responsible for cystic fibrosis (CF), it is unclear how many of them actually contribute to the inherited disease. Now a team of researchers reports significant headway in figuring out which mutations are benign and which are deleterious. In so doing, they have increased the number of known CF-causing mutations from 22 to 127, accounting for 95 percent of the variations found in patients with CF.
In a summary of their research to be published online in Nature Genetics Aug. 25, the scientists say that characterizing those additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will not only bring certainty to families about a CF diagnosis or carrier status, but will also accelerate the design process for new drugs tailored to a particular mutation. There already is one such individualized drug on the market.
"Since not all mutations cause disease, sequencing the DNA in both copies of your CFTR gene and finding an abnormality in one wouldn't tell us if you are a carrier for CF unless we knew if that abnormality causes CF," says Garry Cutting, M.D., professor of pediatrics in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine. "Until this new work, more than a quarter of couples in which both partners were found to carry a CFTR mutation were left wondering if their mutations were going to affect their offspring. Now it's down to 9 percent," he says.
CF is the most common, lethal, recessive genetic disease affecting Caucasians, with approximately 70,000 to 80,000 cases worldwide. When two copies of a defective CFTR gene are inherited, one from each parent, a child's body will not be able to create working CFTR proteins, resulting in the production of thickened mucus, which clogs the lungs and digestive system. Modern treatments to unclog the lungs and address other symptoms have allowed patients to survive into adulthood, but most will still die prematurely of lung disease.
One in 30 Caucasians in the United States is a "carrier" of the disease, meaning their genomes include one abnormal copy of the CFTR gene but they experience no symptoms of the disease, and as many as a million Americans are tested each year for carrier status. If two carriers have children together, each child has a 1-in-4 chance of inheriting two bad copies of CFTR and suffering from the disease. The severity of the disease will depend on which particular gene variations are inherited and how they affect the functioning of the CFTR protein.
In 2012, a drug (ivacaftor) that enhances the function of one specific mutant form of the protein became available. Although the particular mutation targeted is only found in 4 percent of patients with CF, drug companies are already working on drugs to target mutant proteins resulting from other mutations.
"There is very important information in each of these naturally occurring mutations that teaches us more and more about the disease," says Patrick Sosnay, M.D., assistant professor of pulmonary and critical care medicine. "We want to get to a point where we can say, 'This is your mutation, this is what it means and this is how you can treat it.'"
The team began its study with a database containing the genetic information of nearly 40,000 patients with CF. It then examined the 159 mutations that occurred in the database at a frequency of at least 0.01 percent. (Most of the more than 1,900 known mutations are even more rare than that.) The research team analyzed each of these mutations to determine its clinical relevance and its effect on the work of the CFTR protein.
The impact of each mutation on patients' health was assessed by first examining data on the salt concentrations in the sweat of patients bearing each particular mutation. CF causes unusually high amounts of salt to appear in sweat, so a mutation was deemed clinically significant if patients carrying that mutation had high reported salt concentrations.
The team then looked at how each genetic error affected the protein made by the CFTR gene. Eighty of the mutations would prevent the production of any CFTR protein based on the location of the mutation. These were classified as disease-causing, Cutting said. The remaining 77 mutations were tested biochemically in cells to determine the amount of damage sustained by the CFTR protein in each case.
In total, 127 of the 159 mutations were shown to cause CF, if inherited with another CF-causing mutation. Of those, 105 had never before been characterized.
"This new information will give clear answers to tens of thousands of people each year: those being screened as potential carriers, parents of infants who have been flagged during newborn screening and children and adults who are looking for a diagnosis," says Karen Siklosi, M.G.C., a genetic counselor involved in the study.
"It's our hope that the functional data we have provided for these other mutations can be used to find additional drugs for specific CF mutations," says Cutting. "We also believe that the process we followed in this study can be repeated to help characterize many other rare genetic disorders."
This data is already being used by CF clinicians to aid in diagnosis, by public health experts to refine newborn screening and by researchers investigating new therapeutics. The team is also continuing to analyze the rest of the mutations in the database — those with a frequency of less than 0.01 percent — and has already found 49 more that are CF-causing. Updates can be found at the project's website. "We don't want to stop where we are and forget about the patients with the rarest mutations. We will leave no one behind," says Cutting.
Other authors of the report include Kyle Kaniecki, Neeraj Sharma, David Masica, Rachel Karchin and Michelle Lewis of The Johns Hopkins University, and several others from other institutions, including Fredrick Van Goor, Haihui Yu and Philip Thomas.
This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (5R37DK044003, DK49835); Cystic Fibrosis Foundation Therapeutics, Inc.; the Cystic Fibrosis Foundation; and FCT (Portugal).
A portion of the research described in this study was done at Vertex Pharmaceuticals, which manufactures and develops CF drugs. Funding for research described in this study that was performed at The Johns Hopkins University was provided by the Cystic Fibrosis Foundation. Also, Illumina, Inc. produces products whose value could be impacted by the outcome of the study. Van Goor is employed by Vertex Pharmaceuticals. Yu is employed by Vertex Pharmaceuticals and owns stock in the company. Thomas has financial interest in and sponsored research from Reata Pharmaceuticals. Cutting is a paid consultant to Cystic Fibrosis Foundation Therapeutics, Inc.; Illumina, Inc.; and Vertex Pharmaceuticals, and these arrangements have been reviewed and approved by The Johns Hopkins University in accordance with its conflict-of-interest policies.
On the Web:
Link to article: http://dx.doi.org/10.1038/ng.2745
CFTR Gene Project's website: http://www.cftr2.org
Garry Cutting: http://humangenetics.jhmi.edu/index.php/faculty/garry-cutting.html
Patrick Sosnay: http://www.hopkinscf.org/main/aboutus/bioadult_sosnay.html
Media Contacts: Catherine Kolf; 443-287-2251; email@example.com
Ellen Beth Levitt; 410-955-5307; firstname.lastname@example.org
Shawna Williams; 410-955-8236; email@example.com
Catherine Kolf | EurekAlert!
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences